NCT04707196
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 4
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with clinical evidence or history of central nervous system metastasis; Patients with leptomeningeal disease; Patients who have received prior treatment with chemotherapy (except for neoadjuvant/adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor (e.g. Ibrance/palbociclib, abemaciclib/Verzenio, ribociclib/Kisqali); Patients with inflammatory breast cancer
https://ClinicalTrials.gov/show/NCT04707196